Defective regulatory T cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome

Journal of Immunology

Volumn 182, Issue 12, 2009, Pages 8071-8079

  Takahashi, Ryo ^a   Kano, Yoko ^b   Yamazaki, Yoshimi ^b   Kimishima, Momoko ^b   Mizukawa, Yoshiko ^b   Shiohara, Tetsuo ^a,b  

^a KYORIN UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADDRESSIN; CHEMOKINE RECEPTOR CCR4; TRANSCRIPTION FACTOR FOXP3; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRESS SYNDROME; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN DEFECT; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; CELL CULTURE; DRUG ERUPTION; IMMUNOLOGY; PATHOLOGY; PROTEIN TRANSPORT; TIME;

CELLS, CULTURED; DRUG ERUPTIONS; HUMANS; PHENOTYPE; PROTEIN TRANSPORT; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649160590     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804002     Document Type: Article

References (45)

1. Pichler, W. J. 2007. Drug hypersensitivity reactions: classification And relationship to T-cell activation. In Drug Hypersensitivity. W. J. Pichler, ed. Karger, Basel, pp. 168-189.
2. Le Cleach, L., S. Delaire, L. Boumsell, M. Bagot, I. Bourgault-Villada, A. Bensussan, and J. C. Roujeau. 2000. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin. Exp. Immunol. 119: 225-230.
3. Nassif, A., A. Bensussan, L. Boumsell, A. Deniaud, H. Moslehi, P. Wolkenstein, M. Bagot, and J. C. Roujeau. 2004. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy. Clin. Immunol. 114: 1209-1215.
4. Britschgi, M., U. C. Steiner, S. Schmid, J. P. Depta, G. Senti, A. Bircher, C. Burkhart, N. Yawalkar, and W. J. Pichler. 2001. T-cell involvement in druginduced acute generalized exanthematous pustulosis. J. Clin. Invest. 107: 1433-1441.
5. Azukizawa, H., H. Kosaka, S. Sano, W. R. Heath, I. Takahashi, X. H. Gao, Y. Sumikawa, M. Okabe, K. Yoshikawa, and S. Itami. 2003. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur. J. Immunol. 33: 1879-1888.
6. Azukizawa, H., S. Sano, H. Kosaka, Y. Sumikawa, and S. Itami. 2005. Prevention of toxic epidermal necrolysis by regulatory T cells. Eur. J. Immunol. 35: 1722-1730.
7. Suzuki, Y., R. Inagi, T. Aono, K. Yamanishi, and T. Shiohara. 1998. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch. Dermatol. 134: 1108-1112.
8. Kano, Y., K. Hiraharas, K. Sakuma, and T. Shiohara. 2006. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br. J. Dermatol. 155: 301-306.
9. Hashimoto, K., M. Yasukawa, and M. Tohyama. 2003. Human herpesvirus 6 and drug allergy. Curr. Opin. Allergy. Clin. Immunol. 3: 255-260.
10. Kano, Y., M. Inaoka, and T. Shiohara. 2004. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch. Dermatol. 140: 183-188.
11. Sekine, N., T. Motokura, T. Oki, Y. Umeda, N. Sasaki, M. Hayashi, H. Sato, T. Fujita, T. Kaneko, Y. Asano, and K. Kikuchi. 2001. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 285: 1153-1154.
12. Kano, Y., K. Sakuma, and T. Shiohara. 2007. Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome. Br. J. Dermatol. 156: 1061-1063.
13. Gross, A. J., D. Hochberg, W. M. Rand, and D. A. Thorley-Lawson. 2005. EBV and systemic lupus erythematosus: a new perspective. J. Immunol. 174: 6599-6607. (Pubitemid 40705620)
14. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6: 345-352.
15. + T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med. 202: 1549-1561.
16. Dosch, H. M., J. Jason, and E. W. Gelfand. 1982. Transient antibody deficiency and abnormal T-suppressor cells induced by phenytoin. N. Engl. J. Med. 306: 406-409.
17. Kano, Y., K. Hirahara, Y. Mitsuyama, R. Takahashi, and T. Shiohara. 2007. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 62: 1439-1444.
18. Shiohara, T., M. Iijima, Z. Ikezawa, and K. Hashimoto. 2007. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br. J. Dermatol. 156: 1083-1084.
19. Bastuji-Garin, S., B. Rzany, R. S. Stern, N. H. Shear, L. Naldi, and J. C. Roujeau. 1993. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129: 92-96.
20. high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174: 164-173.
21. + FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-β dependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
22. Clark, R. A., and T. S. Kupper. 2007. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood 109: 194-202.
23. Takahashi, R., Y. Mizukawa, Y. Yamazaki, K. Hayakawa, J. Hayakawa, A. Kudo, and T. Shiohara. 2003. In vitro differentiation from naive to mature E-selectin binding CD4 T cells: acquisition of skin-homing properties occurs independently of cutaneous lymphocyte antigen expression. J. Immunol. 171: 5769-5777.
24. + T cells. Eur. J. Immunol. 37: 129-138.
25. Allan, S. E., S. Q. Crome, N. K. Crellin, L. Passerini, T. S. Steiner, R. Bacchetta, M. G. Roncarolo, and M. K. Levings. 2007. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19: 345-354.
26. + regulatory T cells. J. Exp. Med. 194: 847-853.
27. + regulatory T cells bear functional skin-homing receptors. J. Immunol. 177: 4488-4494.
28. Vittorio, C. C., and J. J. Muglia. 1995. Anticonvulsant hypersensitivity syndrome. Arch. Intern. Med. 155: 2285-2290.
29. Azukizawa H, I. S. 2007. Animal models of toxic epidermal necrolysis. In Drug Hypersensitivity. W. J. Pichler, ed. Karger, Basel, pp. 129-139.
30. Campbell, J. J., G. Haraldsen, J. Pan, J. Rottman, S. Qin, P. Ponath, D. P. Andrew, R. Warnke, N. Ruffing, N. Kassam, et al. 1999. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400: 776-780.
31. Shiohara, T., M. Inaoka, and Y. Kano. 2006. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol. Int. 55: 1-8.
32. + T cells selectively kill B lymphocytes. Blood 107: 3925-3932.
33. Kukreja, A., G. Cost, J. Marker, C. Zhang, Z. Sun, K. Lin-Su, S. Ten, M. Sanz, M. Exley, B. Wilson, S. Porcelli, and N. Maclaren. 2002. Multiple immunoregulatory defects in type-1 diabetes. J. Clin. Invest. 109: 131-140.
34. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105: 735-741.
35. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979.
36. Ozaki, N., Y. Miura, and Y. Oiso. 2006. A case of type 1 diabetes followed by methimazole-induced hypersensitivity syndrome. Diabetes Care 29: 1179-1180.
37. Chiou, C. C., W. H. Chung, S. I. Hung, L. C. Yang, and H. S. Hong. 2006. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J. Am. Acad. Dermatol. 54: S14-17.
38. Sutmuller, R. P., M. E. Morgan, M. G. Netea, O. Grauer, and G. J. Adema. 2006. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol. 27: 387-393.
39. Kurt-Jones, E. A., M. Chan, S. Zhou, J. Wang, G. Reed, R. Bronson, M. M. Arnold, D. M. Knipe, and R. W. Finberg. 2004. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl. Acad. Sci. USA 101: 1315-1320.
40. Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. D. Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274: 33419-33425.
41. Roujeau, J. C., and R. S. Stern. 1994. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331: 1272-1285.
42. Miyara, M., Z. Amoura, C. Parizot, C. Badoual, K. Dorgham, S. Trad, M. Kambouchner, D. Valeyre, C. Chapelon-Abric, P. Debre, et al. 2006. The immune paradox of sarcoidosis and regulatory T cells. J. Exp. Med. 203: 359-370.
43. Shelburne, S. A., 3rd, R. J. Hamill, M. C. Rodriguez-Barradas, S. B. Greenberg, R. L. Atmar, D. W. Musher, J. C. Gathe, Jr., F. Visnegarwala, and B. W. Trautner. 2002. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81: 213-227.
44. Tangsinmankong, N., W. Kamchaisatian, J. Lujan-Zilbermann, C. L. Brown, J. W. Sleasman, and P. J. Emmanuel. 2004. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children. J. Allergy. Clin. Immunol. 113: 742-746.
45. + T cell clonal anergy induction during the recovery from lymphopenia. J. Immunol. 176: 5880-5889.